Yuto Yasuda, Hiroaki Ozasa, Young Hak Kim. J Thorac Oncol 2018
Times Cited: 23
Times Cited: 23
Times Cited
Times Co-cited
Similarity
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Leora Horn, Aaron S Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J Hochmair, Florian Huemer, György Losonczy, Melissa L Johnson, Makoto Nishio,[...]. N Engl J Med 2018
Leora Horn, Aaron S Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J Hochmair, Florian Huemer, György Losonczy, Melissa L Johnson, Makoto Nishio,[...]. N Engl J Med 2018
56
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
Patrick A Ott, Elena Elez, Sandrine Hiret, Dong-Wan Kim, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Janice M Mehnert. J Clin Oncol 2017
Patrick A Ott, Elena Elez, Sandrine Hiret, Dong-Wan Kim, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Janice M Mehnert. J Clin Oncol 2017
52
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Scott J Antonia, José A López-Martin, Johanna Bendell, Patrick A Ott, Matthew Taylor, Joseph Paul Eder, Dirk Jäger, M Catherine Pietanza, Dung T Le, Filippo de Braud,[...]. Lancet Oncol 2016
Scott J Antonia, José A López-Martin, Johanna Bendell, Patrick A Ott, Matthew Taylor, Joseph Paul Eder, Dirk Jäger, M Catherine Pietanza, Dung T Le, Filippo de Braud,[...]. Lancet Oncol 2016
52
PD-L1 expression in small cell neuroendocrine carcinomas.
Anne M Schultheis, Andreas H Scheel, Luka Ozretić, Julie George, Roman K Thomas, Thorsten Hagemann, Thomas Zander, Jürgen Wolf, Reinhard Buettner. Eur J Cancer 2015
Anne M Schultheis, Andreas H Scheel, Luka Ozretić, Julie George, Roman K Thomas, Thorsten Hagemann, Thomas Zander, Jürgen Wolf, Reinhard Buettner. Eur J Cancer 2015
39
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).
Shirish M Gadgeel, Nathan A Pennell, Mary Jo Fidler, Balazs Halmos, Philip Bonomi, James Stevenson, Bryan Schneider, Ammar Sukari, Jaclyn Ventimiglia, Wei Chen,[...]. J Thorac Oncol 2018
Shirish M Gadgeel, Nathan A Pennell, Mary Jo Fidler, Balazs Halmos, Philip Bonomi, James Stevenson, Bryan Schneider, Ammar Sukari, Jaclyn Ventimiglia, Wei Chen,[...]. J Thorac Oncol 2018
39
Comprehensive genomic profiles of small cell lung cancer.
Julie George, Jing Shan Lim, Se Jin Jang, Yupeng Cun, Luka Ozretić, Gu Kong, Frauke Leenders, Xin Lu, Lynnette Fernández-Cuesta, Graziella Bosco,[...]. Nature 2015
Julie George, Jing Shan Lim, Se Jin Jang, Yupeng Cun, Luka Ozretić, Gu Kong, Frauke Leenders, Xin Lu, Lynnette Fernández-Cuesta, Graziella Bosco,[...]. Nature 2015
34
Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
Hidenobu Ishii, Koichi Azuma, Akihiko Kawahara, Kazuhiko Yamada, Yohei Imamura, Takaaki Tokito, Takashi Kinoshita, Masayoshi Kage, Tomoaki Hoshino. J Thorac Oncol 2015
Hidenobu Ishii, Koichi Azuma, Akihiko Kawahara, Kazuhiko Yamada, Yohei Imamura, Takaaki Tokito, Takashi Kinoshita, Masayoshi Kage, Tomoaki Hoshino. J Thorac Oncol 2015
30
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
Hui Yu, Cory Batenchuk, Andrzej Badzio, Theresa A Boyle, Piotr Czapiewski, Daniel C Chan, Xian Lu, Dexiang Gao, Kim Ellison, Ashley A Kowalewski,[...]. J Thorac Oncol 2017
Hui Yu, Cory Batenchuk, Andrzej Badzio, Theresa A Boyle, Piotr Czapiewski, Daniel C Chan, Xian Lu, Dexiang Gao, Kim Ellison, Ashley A Kowalewski,[...]. J Thorac Oncol 2017
30
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Luis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J Hochmair, Mustafa Özgüroğlu, Jun Ho Ji,[...]. Lancet 2019
Luis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J Hochmair, Mustafa Özgüroğlu, Jun Ho Ji,[...]. Lancet 2019
30
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
26
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Louis Fehrenbacher, Alexander Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazieres, Keunchil Park, David Smith, Angel Artal-Cortes, Conrad Lewanski,[...]. Lancet 2016
Louis Fehrenbacher, Alexander Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazieres, Keunchil Park, David Smith, Angel Artal-Cortes, Conrad Lewanski,[...]. Lancet 2016
26
26
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Martin Reck, Alexander Luft, Aleksandra Szczesna, Libor Havel, Sang-We Kim, Wallace Akerley, Maria Catherine Pietanza, Yi-Long Wu, Christoph Zielinski, Michael Thomas,[...]. J Clin Oncol 2016
Martin Reck, Alexander Luft, Aleksandra Szczesna, Libor Havel, Sang-We Kim, Wallace Akerley, Maria Catherine Pietanza, Yi-Long Wu, Christoph Zielinski, Michael Thomas,[...]. J Clin Oncol 2016
26
Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
Kentaro Inamura, Yusuke Yokouchi, Maki Kobayashi, Hironori Ninomiya, Rie Sakakibara, Makoto Nishio, Sakae Okumura, Yuichi Ishikawa. Cancer Med 2017
Kentaro Inamura, Yusuke Yokouchi, Maki Kobayashi, Hironori Ninomiya, Rie Sakakibara, Makoto Nishio, Sakae Okumura, Yuichi Ishikawa. Cancer Med 2017
26
Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.
Hye Sook Kim, Jeong Hyeon Lee, Soo Jeong Nam, Chan-Young Ock, Jae-Woo Moon, Chong Woo Yoo, Geon Kook Lee, Ji-Youn Han. J Thorac Oncol 2018
Hye Sook Kim, Jeong Hyeon Lee, Soo Jeong Nam, Chan-Young Ock, Jae-Woo Moon, Chong Woo Yoo, Geon Kook Lee, Ji-Youn Han. J Thorac Oncol 2018
21
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.
M Reck, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, M Sebastian, H Lu, J-M Cuillerot, T J Lynch. Ann Oncol 2013
M Reck, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, M Sebastian, H Lu, J-M Cuillerot, T J Lynch. Ann Oncol 2013
21
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, Emiliano Calvo, Paolo A Ascierto, Akin Atmaca, Naiyer A Rizvi, Fred R Hirsch, Giovanni Selvaggi, Joseph D Szustakowski,[...]. Cancer Cell 2018
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, Emiliano Calvo, Paolo A Ascierto, Akin Atmaca, Naiyer A Rizvi, Fred R Hirsch, Giovanni Selvaggi, Joseph D Szustakowski,[...]. Cancer Cell 2018
21
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Fred R Hirsch, Abigail McElhinny, Dave Stanforth, James Ranger-Moore, Malinka Jansson, Karina Kulangara, William Richardson, Penny Towne, Debra Hanks, Bharathi Vennapusa,[...]. J Thorac Oncol 2017
Fred R Hirsch, Abigail McElhinny, Dave Stanforth, James Ranger-Moore, Malinka Jansson, Karina Kulangara, William Richardson, Penny Towne, Debra Hanks, Bharathi Vennapusa,[...]. J Thorac Oncol 2017
21
High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
Yih-Leong Chang, Ching-Yao Yang, Yen-Lin Huang, Chen-Tu Wu, Pan-Chyr Yang. Oncotarget 2017
Yih-Leong Chang, Ching-Yao Yang, Yen-Lin Huang, Chen-Tu Wu, Pan-Chyr Yang. Oncotarget 2017
21
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
21
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
L Bonanno, A Pavan, M V Dieci, E Di Liso, M Schiavon, G Comacchio, I Attili, G Pasello, F Calabrese, F Rea,[...]. Eur J Cancer 2018
L Bonanno, A Pavan, M V Dieci, E Di Liso, M Schiavon, G Comacchio, I Attili, G Pasello, F Calabrese, F Rea,[...]. Eur J Cancer 2018
21
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
21
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
21
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.
Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Lionel Uwer, José Hureaux, Florian Guisier, Delphine Carmier, Jeannick Madelaine, Josiane Otto,[...]. J Thorac Oncol 2019
Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Lionel Uwer, José Hureaux, Florian Guisier, Delphine Carmier, Jeannick Madelaine, Josiane Otto,[...]. J Thorac Oncol 2019
21
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
21
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
Hyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, Jan H M Schellens, Steven Kao, Wilson H Miller, Jean-Pierre Delord, Bo Gao, David Planchard, Maya Gottfried,[...]. J Thorac Oncol 2020
Hyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, Jan H M Schellens, Steven Kao, Wilson H Miller, Jean-Pierre Delord, Bo Gao, David Planchard, Maya Gottfried,[...]. J Thorac Oncol 2020
21
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.
M Ilie, E Long-Mira, C Bence, C Butori, S Lassalle, L Bouhlel, L Fazzalari, K Zahaf, S Lalvée, K Washetine,[...]. Ann Oncol 2016
M Ilie, E Long-Mira, C Bence, C Butori, S Lassalle, L Bouhlel, L Fazzalari, K Zahaf, S Lalvée, K Washetine,[...]. Ann Oncol 2016
21
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.
Haidong Tang, Yong Liang, Robert A Anders, Janis M Taube, Xiangyan Qiu, Aditi Mulgaonkar, Xin Liu, Susan M Harrington, Jingya Guo, Yangchun Xin,[...]. J Clin Invest 2018
Haidong Tang, Yong Liang, Robert A Anders, Janis M Taube, Xiangyan Qiu, Aditi Mulgaonkar, Xin Liu, Susan M Harrington, Jingya Guo, Yangchun Xin,[...]. J Clin Invest 2018
17
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
17
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Sandip Pravin Patel, Razelle Kurzrock. Mol Cancer Ther 2015
Sandip Pravin Patel, Razelle Kurzrock. Mol Cancer Ther 2015
17
Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer.
Julie George, Motonobu Saito, Koji Tsuta, Reika Iwakawa, Kouya Shiraishi, Andreas H Scheel, Shinsuke Uchida, Shun-Ichi Watanabe, Ryo Nishikawa, Masayuki Noguchi,[...]. Clin Cancer Res 2017
Julie George, Motonobu Saito, Koji Tsuta, Reika Iwakawa, Kouya Shiraishi, Andreas H Scheel, Shinsuke Uchida, Shun-Ichi Watanabe, Ryo Nishikawa, Masayuki Noguchi,[...]. Clin Cancer Res 2017
17
PD-L1 and c-MET expression and survival in patients with small cell lung cancer.
Lulu Miao, Yunyun Lu, Yanjun Xu, Gu Zhang, Zhiyu Huang, Lei Gong, Yun Fan. Oncotarget 2017
Lulu Miao, Yunyun Lu, Yanjun Xu, Gu Zhang, Zhiyu Huang, Lei Gong, Yun Fan. Oncotarget 2017
17
Small-cell lung cancer: what we know, what we need to know and the path forward.
Adi F Gazdar, Paul A Bunn, John D Minna. Nat Rev Cancer 2017
Adi F Gazdar, Paul A Bunn, John D Minna. Nat Rev Cancer 2017
17
Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Anna Sophie Berghoff, Gerda Ricken, Dorothee Wilhelm, Orsolya Rajky, Georg Widhalm, Karin Dieckmann, Peter Birner, Rupert Bartsch, Matthias Preusser. J Neurooncol 2016
Anna Sophie Berghoff, Gerda Ricken, Dorothee Wilhelm, Orsolya Rajky, Georg Widhalm, Karin Dieckmann, Peter Birner, Rupert Bartsch, Matthias Preusser. J Neurooncol 2016
17
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
T A Chan, M Yarchoan, E Jaffee, C Swanton, S A Quezada, A Stenzinger, S Peters. Ann Oncol 2019
T A Chan, M Yarchoan, E Jaffee, C Swanton, S A Quezada, A Stenzinger, S Peters. Ann Oncol 2019
17
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll. Cancer Cell 2015
Suzanne L Topalian, Charles G Drake, Drew M Pardoll. Cancer Cell 2015
17
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
Daniel Carvajal-Hausdorf, Mehmet Altan, Vamsidhar Velcheti, Scott N Gettinger, Roy S Herbst, David L Rimm, Kurt A Schalper. J Immunother Cancer 2019
Daniel Carvajal-Hausdorf, Mehmet Altan, Vamsidhar Velcheti, Scott N Gettinger, Roy S Herbst, David L Rimm, Kurt A Schalper. J Immunother Cancer 2019
17
PD-L1 expression in neuroendocrine tumors of the lung.
Kenjiro Tsuruoka, Hidehito Horinouchi, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Keisuke Asakura, Kazuo Nakagawa, Hiroyuki Sakurai,[...]. Lung Cancer 2017
Kenjiro Tsuruoka, Hidehito Horinouchi, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Keisuke Asakura, Kazuo Nakagawa, Hiroyuki Sakurai,[...]. Lung Cancer 2017
17
Current standards for clinical management of small cell lung cancer.
Anna F Farago, Florence K Keane. Transl Lung Cancer Res 2018
Anna F Farago, Florence K Keane. Transl Lung Cancer Res 2018
13
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Heng Lin, Shuang Wei, Elaine M Hurt, Michael D Green, Lili Zhao, Linda Vatan, Wojciech Szeliga, Ronald Herbst, Paul W Harms, Leslie A Fecher,[...]. J Clin Invest 2018
Heng Lin, Shuang Wei, Elaine M Hurt, Michael D Green, Lili Zhao, Linda Vatan, Wojciech Szeliga, Ronald Herbst, Paul W Harms, Leslie A Fecher,[...]. J Clin Invest 2018
13
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
Joachim von Pawel, Robert Jotte, David R Spigel, Mary E R O'Brien, Mark A Socinski, Jörg Mezger, Martin Steins, Léon Bosquée, Jeffrey Bubis, Kristiaan Nackaerts,[...]. J Clin Oncol 2014
Joachim von Pawel, Robert Jotte, David R Spigel, Mary E R O'Brien, Mark A Socinski, Jörg Mezger, Martin Steins, Léon Bosquée, Jeffrey Bubis, Kristiaan Nackaerts,[...]. J Clin Oncol 2014
13
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
John R Eckardt, Joachim von Pawel, Jean-Louis Pujol, Zsolt Papai, Elisabeth Quoix, Andrea Ardizzoni, Ruth Poulin, Alaknanda J Preston, Graham Dane, Graham Ross. J Clin Oncol 2007
John R Eckardt, Joachim von Pawel, Jean-Louis Pujol, Zsolt Papai, Elisabeth Quoix, Andrea Ardizzoni, Ruth Poulin, Alaknanda J Preston, Graham Dane, Graham Ross. J Clin Oncol 2007
13
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
13
Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer.
T Yazawa, H Kamma, M Fujiwara, M Matsui, H Horiguchi, H Satoh, M Fujimoto, K Yokoyama, T Ogata. J Pathol 1999
T Yazawa, H Kamma, M Fujiwara, M Matsui, H Horiguchi, H Satoh, M Fujimoto, K Yokoyama, T Ogata. J Pathol 1999
13
Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma.
Takuya Yazawa, Takaaki Ito, Hiroshi Kamma, Takehisa Suzuki, Koji Okudela, Hiroyuki Hayashi, Hisashi Horiguchi, Takesaburo Ogata, Hideaki Mitsui, Masaichi Ikeda,[...]. Am J Pathol 2002
Takuya Yazawa, Takaaki Ito, Hiroshi Kamma, Takehisa Suzuki, Koji Okudela, Hiroyuki Hayashi, Hisashi Horiguchi, Takesaburo Ogata, Hideaki Mitsui, Masaichi Ikeda,[...]. Am J Pathol 2002
13
Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer.
Tian Tian, Xiaobin Gu, Bo Zhang, Yang Liu, Chao Yuan, Lijuan Shao, Yajun Guo, Kexing Fan. Cancer Biomark 2015
Tian Tian, Xiaobin Gu, Bo Zhang, Yang Liu, Chao Yuan, Lijuan Shao, Yajun Guo, Kexing Fan. Cancer Biomark 2015
13
Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate.
Wei Wang, Philip Hodkinson, Fiona McLaren, Alison MacKinnon, William Wallace, Sarah Howie, Tariq Sethi. Int J Cancer 2012
Wei Wang, Philip Hodkinson, Fiona McLaren, Alison MacKinnon, William Wallace, Sarah Howie, Tariq Sethi. Int J Cancer 2012
13
Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer.
A Doyle, W J Martin, K Funa, A Gazdar, D Carney, S E Martin, I Linnoila, F Cuttitta, J Mulshine, P Bunn. J Exp Med 1985
A Doyle, W J Martin, K Funa, A Gazdar, D Carney, S E Martin, I Linnoila, F Cuttitta, J Mulshine, P Bunn. J Exp Med 1985
13
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.
Ramaswamy Govindan, Nathan Page, Daniel Morgensztern, William Read, Ryan Tierney, Anna Vlahiotis, Edward L Spitznagel, Jay Piccirillo. J Clin Oncol 2006
Ramaswamy Govindan, Nathan Page, Daniel Morgensztern, William Read, Ryan Tierney, Anna Vlahiotis, Edward L Spitznagel, Jay Piccirillo. J Clin Oncol 2006
13
Regulation and Function of the PD-L1 Checkpoint.
Chong Sun, Riccardo Mezzadra, Ton N Schumacher. Immunity 2018
Chong Sun, Riccardo Mezzadra, Ton N Schumacher. Immunity 2018
13
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.